Ikris Pharma
About Us Named Patient Program
Contact Us
Cablivi

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

You can also access detailed information by clicking Login in the website header.

Cablivi

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Cablivi
Generic Name (API): Caplacizumab
Dosage Form & Strength: 10 mg
Route: Intravenous (IV) and Subcutaneous (SC) injection
Drug Class: Von Willebrand factor-directed antibody fragment

Manufacturer / Innovator:

Germany

Regulatory Approval:

  • US FDA
Family enjoying life with Named Patient Program access

Your Trustedworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant
Licensed Wholesale distributor

What Is Cablivi Used For?

Cablivi (caplacizumab-yhdp) is a von Willebrand factor-directed antibody fragment. It is indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of:

  • Acquired thrombotic thrombocytopenic purpura (aTTP) in adults

It is a prescription biologic used in a hospital setting alongside plasma exchange therapy, and must be administered under the supervision of a qualified hematologist.

Recommended Dosage

  • Day 1: 11 mg IV bolus at least 15 minutes before plasma exchange, followed by 11 mg subcutaneously after plasma exchange
  • During daily plasma exchange: 11 mg subcutaneously following each plasma exchange session
  • After plasma exchange ends: 11 mg subcutaneously once daily for 30 days; may be extended up to 28 additional days if signs of underlying disease persist

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Cablivi Warnings and Precautions

  • Bleeding risk: Serious and fatal bleeding can occur, with higher risk in patients with underlying coagulopathies or those on antiplatelet agents or anticoagulants. Common bleeding events include nosebleeds and gum bleeding; serious events such as subarachnoid hemorrhage have been reported.
  • Hypersensitivity reactions: Including urticaria, have occurred. Cablivi is contraindicated in patients with a history of severe hypersensitivity to caplacizumab.
  • Bleeding risk with invasive procedures: Discontinuation may be needed before planned surgery or invasive procedures, per your doctor's assessment.

How to Access Cablivi in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Cablivi to India?

Cablivi (caplacizumab-yhdp) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

  • A valid prescription from a qualified doctor
  • The patient's diagnostic reports confirming aTTP diagnosis
  • Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit. Given the urgent nature of aTTP treatment, expedited coordination is prioritized.

Is Cablivi available in India?

Cablivi (caplacizumab-yhdp injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Cablivi is not commercially marketed in India.

However, patients in India can legally access Cablivi through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.

Cablivi has been FDA approved since 2019, ensuring full transparency throughout the process.

Cablivi can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) can source Cablivi from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Cablivi requires cold-chain handling throughout transit and must be kept refrigerated between 2°C to 8°C, protected from light. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For Cablivi cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability of Cablivi Across Major Cities in India

Patients across India can access Cablivi through regulated import pathways, with delivery arranged to the treating hospital based on a valid hematologist's prescription, alongside plasma exchange therapy.

Mumbai

A major hematology hub with institutions like Tata Memorial, Mumbai coordinates access to aTTP therapies like Cablivi for eligible patients.

Delhi

As part of the Delhi NCR region, the city has a strong concentration of hematology specialists, making it a key location for accessing aTTP treatments.

Bangalore

With a growing network of multispecialty hospitals, Bangalore supports access to Cablivi through structured import pathways guided by treating specialists.

Chennai

Home to several reputed hematology centers, Chennai facilitates access to Cablivi for patients with acquired thrombotic thrombocytopenic purpura.

Hyderabad

A growing hub for specialty care, Hyderabad supports coordinated access to Cablivi for eligible patients under specialist supervision.

Kolkata

Eastern India's leading medical centers in Kolkata coordinate Cablivi access for patients with aTTP.

Pune

With an expanding base of hematology clinics, Pune facilitates timely access to Cablivi under prescription.

Ahmedabad

Gujarat's leading hospitals support regulated access to Cablivi for eligible patients.

Kochi

Kerala's healthcare network, including major hospitals in Kochi, coordinates access to advanced biologics like Cablivi.

Chandigarh

Serving North India, Chandigarh's specialist centers facilitate access to Cablivi for patients from Punjab, Haryana, and Himachal Pradesh.

Jaipur

Rajasthan's leading hospitals support patient access to Cablivi through the Named Patient Program.

Lucknow

A key referral center for North India, Lucknow facilitates coordinated access to Cablivi under specialist care.

Bhubaneswar

Odisha's growing specialty healthcare sector supports patient access to Cablivi.

Guwahati

As a referral hub for the North-East, Guwahati facilitates access to Cablivi for patients across the region.

Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.

Written By:

Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO

Medically Reviewed By:

Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More